As per the collaboration, the current scientific knowledge on Ipsogen’s MapQuant Dx Grade Genomic, HER2 and HR tests, will be increased to new data established from a large population of patients treated at the Institut Curie.
The aim of this collaboration is to evaluate these tests in comparision to current breast cancer characterization techniques. Ipsogen said that the new tests could represent, for oncologists and pathologists, helpful decision-making tools enabling them to improve the diagnostic process and optimally adapt their therapeutic strategy to each patient.
The genomic analysis of 200 breast tumors will be performed on the Institut Curie’s molecular diagnostic platform, using the expertise of translational research department and clinical teams specialized in breast cancer, and Ipsogen.
Sergio Roman-Roman, head of Translational Research at the Institut Curie, said: “The existence, at the Institut Curie, of a bank of well-characterized human tumor samples, as well as a particularly strong genomic analysis platform, makes it possible to conduct a reliable assessment of molecular diagnostic tools such as the one that is the subject of this collaboration.
“The stakes are high because these tools, once validated via research can be a aid to make therapeutic decisions for women with breast cancer.”
Vincent Fert, CEO of Ipsogen, said: “The collaboration will also enable us, as we have already successfully done in onco hematology, to continue collaborating with oncologists to develop products that meet their clinical needs in breast cancer.”
